Navigation Links
Resverlogix Scientific Data Presented at EAS Congress
Date:6/22/2010

New data from Phase 1b/2a trial included

TSX Exchange Symbol: RVX

HAMBURG, Germany and CALGARY, AB, June 22 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that key scientific data was communicated in an oral presentation highlighting the novel features of the Company's lead drug RVX-208 at the European Atherosclerosis Society Congress (EAS) conference being held in Hamburg, Germany. The presentation titled "RVX-208 given orally raises plasma ApoA-I and HDL in human clinical trials," was presented by Dr. Norman Wong, MD, Chief Scientific Officer of Resverlogix.

"The data presented in Germany today further highlights that patients with low HDL/Apo-Al benefit most. For those patients in the highest risk category, subjects with low baseline HDL/Apo-Al, our data demonstrated that RVX-208 increased plasma levels of Apo-Al in the order of 13.25% compared to placebo. This data, combined with similar low baseline HDL/Apo A-l data analysis of the upcoming ASSERT trial data will further support the design of a very effective and efficient ASSURE trial," said Donald J. McCaffrey, President & CEO of Resverlogix.

Resverlogix recently completed a Phase 2 clinical trial called ASSERT to study RVX-208 an oral small molecule therapy for the treatment of atherosclerosis. The ASSERT trial enrolled subjects with stable coronary artery disease. A second planned Phase 2 trial, designated ASSURE, will include subjects with acute coronary syndrome and coronary artery disease of whom all will be examined with intravascular ultrasound (IVUS). Both the ASSERT and ASSURE
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Resverlogix Completes Dosing for ASSERT Trial
2. Resverlogix Notice of Conference Call & Webcast for Year End Update
3. Resverlogix Activates First Site for ASSURE 1 Clinical Trial
4. Resverlogix Completes Patient Recruitment for ASSERT Trial
5. Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors
6. Resverlogix Presenting at Biotech Showcase
7. Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
8. Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan
9. Resverlogix Appoints A. Brad Cann as Chief Financial Officer
10. Resverlogix RVX-208 Second Clinical Trial Demonstrates Success on Key Reverse Cholesterol Transport Markers
11. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... ... 26, 2015 , ... Lee Biosolutions, a global biotech healthcare ... of highly valued cardiac markers used in early detection of heart disease due ... has led to the development and commercialization of important cardiac biomarkers used in ...
(Date:8/26/2015)... -- Intrexon Corporation (NYSE: XON ), a leader ... previously announced public offering of common stock, including the ... to purchase an additional 731,707 shares of common stock ...  The exercise of the underwriters, option brought the total ... to 5,609,756 shares and increased the total gross proceeds ...
(Date:8/26/2015)... After litigating and negotiating patent infringement claims brought ... United States patent RE43,651 (the ,651 patent), ... United States without any admission or concession of ... a result of the parties, settlement, the US District Court ... dismissed the case without prejudice. Under the terms ...
(Date:8/26/2015)... Boston, MA (PRWEB) , ... August 26, 2015 , ... ... venue for Boston adult stem cell technology start-up company Asymmetrex to share ... widely the capabilities of a new biomarker for counting adult tissue stem cells. , ...
Breaking Biology Technology:Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4P2i Settles United States Litigation 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 4
... InterMune, Inc. (Nasdaq: ITMN ) today announced that ... InterMune, will present at Citi,s 4th Annual Biotech Day in ... EDT. To access a live audio webcast of the ... the investor relations page of InterMune,s corporate website at ...
... field of molecular diagnostics for lung cancer, has announced that Stephen ... Ph.D. has joined the company as Vice President of Operations and ... ... 2009 -- Allegro Diagnostics, a leader in the field of molecular ...
... Therapeutics, Inc. (Nasdaq: NLTX ), a leading company ... announced today that, in the course of reviewing the Investigational ... U.S. Food and Drug Administration (FDA) to support the initiation ... the treatment of acute heart failure, the FDA has placed ...
Cached Biology Technology:Allegro Diagnostics Expands Board and Executive Team 2Allegro Diagnostics Expands Board and Executive Team 3Allegro Diagnostics Expands Board and Executive Team 4Nile Therapeutics Provides Update on Phase II CD-NP Clinical Trial for Acute Heart Failure 2
(Date:8/18/2015)... Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ) ... Biometric Authentication & Identification Market: Focus On Modality, ... report to their offering. ... is expected to grow at an estimated CAGR ... over $25 billion (approximately) by 2020 as per ...
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that four of its ... solution, have officially been named FIDO Certified™ by ... of the certification, Synaptics, Natural ID™ fingerprint solutions ... Authentication Framework (UAF) standard and are interoperable among ...
(Date:8/6/2015)... and TELTOW, Germany , August 6, ... Conference, SensoMotoric Instruments (SMI) shows the world,s ... , based on Epson,s Moverio BT-200 see-through head ... With this new solution, unprecedented quality and efficiency is ... with context-sensitive displays. For the first time, professionals and ...
Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... help scientists "build" new biological systems, Princeton University scientists ... enable the growth of living cells. The team ... nature, and the scientists showed that they can produce ... as proteins produced by nature,s own toolkit. ...
... ATHENS, Ohio (Jan. 6, 2011) Ohio University ... the bioengineering profession,s highest honor, the Fritz J. and ... Hood of Seattle, Washington, for his discoveries related to ... president and co-founder of the Institute for Systems Biology, ...
... at the University of Connecticut Health Center have identified a ... a predictor of heart attack. Their research, led by ... Cardiology Center, is published in the Jan. 11 issue of ... It found heart attack patients had elevated levels of the ...
Cached Biology News:Princeton scientists construct synthetic proteins that sustain life 2Princeton scientists construct synthetic proteins that sustain life 3DNA sequencing pioneer receives 2011 Russ Prize 2DNA sequencing pioneer receives 2011 Russ Prize 3